Neurotropic Effect of Botulinum Toxin and the Potential of Specific Serum Therapy in Botulism (Review)

INTRODUCTION. The outbreak of foodborne botulism that occurred in Russia in June 2024 once again demonstrated the danger of this rather rare but severe infectious disease caused by ingesting botulinum neurotoxin. The only aetiological treatment for botulism is currently the administration of antitoxins against various serotypes of botulinum toxin. However, antitoxins do not provide rapid regression of neurological symptoms, which may raise doubts about the effectiveness of the selected treatment option. It is impossible to assess the potential of specific treatment without understanding the mechanisms of action of botulinum toxin and antitoxin.

AIM. This study aimed to systemise information on the mechanism underlying the damaging effect of botulinum neurotoxin, aetiological antitoxin treatment, and the patient recovery process.

DISCUSSION. The mechanism underlying the damaging effect of botulinum neurotoxin consists in the destruction of SNARE proteins in presynaptic cholinergic nerve terminals, which disrupts the release of acetylcholine into the synaptic cleft and the transmission of excitation between neurons. The lack of acetylcholine at the neuromuscular junction results in a distinctive form of persistent flaccid paralysis. The specific mechanism of action of botulinum toxin determines the treatment strategy, which includes a set of life-sustaining measures and the earliest possible antiserum administration. If used within 48 hours from the onset of symptoms, botulinum antitoxin binds botulinum toxin circulating in the blood, which stops the progression of paralysis and prevents further disorders in patients. However, botulinum antitoxin cannot neutralise the effect of the toxin that has already bound to nerve receptors, so clinical symptoms may worsen within 12 hours after antiserum administration. Restoration of normal neuronal transmission occurs through the formation of new axonal sprouts and can take a long time.

CONCLUSIONS. Antitoxin administration is effective and irreplaceable in the aetiological treatment of botulism. Nevertheless, the duration of recovery depends on the speed of reinnervation and restoration of transmission at the neuromuscular junction.

1. Nikiforov VV. Botulism. St. Petersburg: Eco-Vector; 2024 (In Russ.). EDN: NDPUMZ

2. Eser F, Hasanoğlu İ, Kayaaslan B, Kaya Kalem A, Bilen Ş, Orhan G, Güner R. Iatrogenic botulism cases after gastric and axillary application of botulinum toxin and review of literature. J Infect Dev Ctries. 2024;18(3):480–7. https://doi.org/10.3855/jidc.18868

3. Rasetti-Escargueil C, Lemichez E, Popoff MR. Public health risk associated with botulism as foodborne zoonoses. Toxins (Basel). 2019;12(1):17. https://doi.org/10.3390/toxins12010017

4. Lonati D, Schicchi A, Crevani M, Buscaglia E, Scaravaggi G, Maida F, et al. Foodborne botulism: clinical diagnosis and medical treatment. Toxins (Basel). 2020;12(8):509. https://doi.org/10.3390/toxins12080509

5. Poulain B, Popoff MR. Why are botulinum neurotoxin-producing bacteria so diverse and botulinum neurotoxins so toxic? Toxins (Basel). 2019;11(1):34. https://doi.org/10.3390/toxins11010034

6. Eswaramoorthy S, Kumaran D, Keller J, Swaminathan S. Role of metals in the biological activity of Clostridium botulinum neurotoxins. Biochemistry. 2004;43(8):2209–16. https://doi.org/10.1021/bi035844k

7. Chen S, Barbieri JT. Association of botulinum neurotoxin serotype. A light chain with plasma membrane-bound SNAP25. J Biol Chem. 2011;286(17):15067–72. https://doi.org/10.1074/jbc.M111.224493

8. Rawson AM, Dempster AW, Humphreys CM, Minton NP. Pathogenicity and virulence of Clostridium botulinum. Virulence. 2023;14(1):2205251. https://doi.org/10.1080/21505594.2023.2205251

9. Yu Z, Liu D, Wu C, Zhao W. Intestinal absorption of bioactive oligopeptides: paracellular transport and tight junction modulation. Food Funct. 2024;15(12):6274–88. https://doi.org/10.1039/d4fo00529e

10. Matsumura T. Mechanism of intestinal absorption of botulinum neurotoxin complex. Jpn J Bacteriol. 2019;74(3):167–75. https://doi.org/10.3412/jsb.74.167

11. Amatsu S, Fujinaga Y. Botulinum hemagglutinin: critical protein for adhesion and absorption of neurotoxin complex in host intestine. Methods Mol Biol. 2020;2132:183–90. https://doi.org/10.1007/978-1-0716-0430-4_19

12. Lee K, Zhong X, Gu S, Kruel AM, Dorner MB, Perry K, et al. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science. 2014;344(6190):1405–10. https://doi.org/10.1126/science.1253823

13. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35. https://doi.org/10.1124/pr.116.012658

14. Poulain B, Lemichez E, Popoff MR. Neuronal selectivity of botu linum neurotoxins. Toxicon. 2020;178:20–32. https://doi.org/10.1016/j.toxicon.2020.02.006

15. Yamamoto H, Ida T, Tsutsuki H, Mori M, Matsumoto T, Kohda T, et al. Specificity of botulinum protease for human VAMP family proteins. Microbiol Immunol. 2012;56(4):245–53. https://doi.org/10.1111/j.1348-0421.2012.00434.x

16. Connan C, Popoff MR. Two-component systems and toxinogenesis regulation in Clostridium botulinum. Res Microbiol. 2015;166(4):332–43. https://doi.org/10.1016/j.resmic.2014.12.012

17. Han J, Pluhackova K, Böckmann RA. The multifaceted role of snare proteins in membrane fusion. Front Physiol. 2017;8:5. https://doi.org/10.3389/fphys.2017.00005

18. Jahn R, Cafiso DC, Tamm LK. Mechanisms of SNARE proteins in membrane fusion. Nat Rev Mol Cell Biol. 2024;25(2):101–18. https://doi.org/10.1038/s41580-023-00668-x

19. Rossi R, Arjmand S, Bærentzen SL, Gjedde A, Landau AM. Synaptic vesicle glycoprotein 2A: features and functions. Front Neurosci. 2022;16:864514. https://doi.org/10.3389/fnins.2022.864514

20. Pirazzini M, Azarnia Tehran D, Leka O, Zanetti G, Rossetto O, Montecucco C. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Bio chim Biophys Acta. 2016;1858(3):467–74. https://doi.org/10.1016/j.bbamem.2015.08.014

21. Păuna AM, Crăciun MD, Sîrbu A, Popescu R, Enciu BG, Chivu CD, et al. Botulism cases in romania-an overview of 14-year national surveillance data. Biomedicines. 2024;12(5):1058. https://doi.org/10.3390/biomedicines12051058

22. Reznik AV. The pharmacology of botulinum toxin type A. In: Sabuncuoglu S, ed. Botulinum toxin — recent topics and applications. Intech Open; 2022. https://doi.org/10.5772/intechopen.101315

23. Marchand-Pauvert V, Aymard C, Giboin LS, Dominici F, Rossi A, Mazzocchio R. Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol. 2013;591(4):1017–29. https://doi.org/10.1113/jphysiol.2012.239178

24. Harvey RR, Cooper R, Bennett S, Richardson M, Duke D, Stoughton C, et al. Outbreak of foodborne botulism in an immigrant community: overcoming delayed disease recognition, ambiguous epidemiologic links, and cultural barriers to identify the cause. Clin Infect Dis. 2017;66( suppl_1):82–4. https://doi.org/10.1093/cid/cix817

25. Ni SA, Brady MF. Botulism Antitoxin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

26. Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK, et al. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis. 2017;66(suppl_1):57–64. https://doi.org/10.1093/cid/cix816

27. Chalk CH, Benstead TJ, Pound JD, Keezer MR. Me dical treatment for botulism. Cochrane Database Syst Rev. 2019;4(4):CD008123. https://doi.org/10.1002/14651858.CD008123.pub4

28. Chatham-Stephens K, Fleck-Derderian S, Johnson SD, Sobel J, Rao AK, Meaney-Delman D. Clinical features of foodborne and wound botulism: a syste matic review of the literature, 1932–2015. Clin Infect Dis. 2017;66(suppl_1):11–6. https://doi.org/10.1093/cid/cix811

29. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm Rep. 2021;70(2):1–30. https://doi.org/10.15585/mmwr.rr7002a1

30. Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol. 1999;38:641–55. https://doi.org/10.1046/j.1365-4362.1999.00722.x

31. Tolmacheva VA. Poststroke spasticity: an individualized approach to treatment. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):71–6 (In Russ.). https://doi.org/10.14412/2074-2711-2016-4-71-76

32. O’Horo JC, Harper EP, El Rafei A, Ali R, DeSimone DC, Sakusic A, et al. Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923–2016. Clin Infect Dis. 2017;66(suppl_1):43–56. https://doi.org/10.1093/cid/cix815

33. Nikiforov VV, Tomilin YN, Davydov AV, Zimin PE, Aleynikova OI. The case of severe botulism: artificial ventilation of lungs for 127 days. Epidemiology and Infectious Diseases. 2013;18(6):49–57 (In Russ.). https://doi.org/10.17816/EID40793

34. Lonati D, Flore L, Vecchio S, Giampreti A, Petrolini VM, Anniballi F, et al. Clinical management of foodborne botulism poisoning in emergency setting: an Italian case series. Clin Toxicol. 2015;53:338.

35.

36.